✦ LIBER ✦

Safety of picotamide, an antiplatelet agent, in an 18-month, double-blind, placebo-controlled, multicenter trial in 2304 patients with peripheral vascular disease

✍ Scribed by F. Violi; A. Longoni; M. Maderna; C. Castiglioni; F. Balsano

Book ID: 117090709
Publisher: Elsevier Science
Year: 1993
Tongue: English
Weight: 497 KB
Volume: 54
Category: Article
ISSN: 0011-393X
DOI: 10.1016/s0011-393x(05)80624-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A double blind placebo controlled trial

A double blind placebo controlled trial of intravenous prostacyclin (PGI2) in 108 patients with ischaemic peripheral vascular disease

✍ I. Virgolini; P. Fitscha; O.I. Linet; J. O'Grady; H. Sinzinger 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 575 KB

Effects of taprostene, a chemically stab

Effects of taprostene, a chemically stable prostacyclin analogue, in patients with ischaemic peripheral vascular disease: A placebo controlled double-blind trial

✍ Virgolini, I.; Fitscha, P.; O'Grady, J.; Barth, H.; Sinzinger, H. 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 437 KB

55 HEMODYNAMIC EFFECTS AND SAFETY OF ONE

55 HEMODYNAMIC EFFECTS AND SAFETY OF ONE-MONTH SIMVASTATIN TREATMENT IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION. A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER TRIAL

✍ J.G. Abraldes; A. Albillos; J. Turnes; R. Banares; R. Gonzalez; M. Gonzalez; J.C 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Efficacy and safety of high-dose pravast

Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial

✍ James H. Lewis; Mary Ellen Mortensen; Steven Zweig; Mary Jean Fusco; Jeffrey R. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 2 views

The hepatotoxic potential of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in patients with underlying chronic liver disease remains controversial. We performed a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial that compared pravastatin (80 mg) to a place

8.3Safety of regadenoson, an adenosine A

8.3Safety of regadenoson, an adenosine A2A receptor agonist, in patients with asthma: a randomised, double-blind, placebo-controlled trial

✍ LEAKER, B; OCONNOR, B; OLMSTED, A; MATHUR, V; LIEU, H 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 62 KB

Efficacy and safety of bifeprunox in pat

Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study

✍ Daniel E. Casey; Earl E. Sands; Jens Heisterberg; Hwa-Ming Yang 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 291 KB